Content Rheum
Interleukin-23 Inhibition
FAQs
Click a title to watch the FAQ
​
Define, compare, and contrast humoral and cell-mediated immunity
​
​
What is the role of the IL23/IL17 axis in rheumatic disease?
​
Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.
​
Why is Binding CD64+ Important When Discussing IL23 Directed Therapy
​
How does axial PsA differ from AS clinically, genetically, and radiographically
​
How do you interpret radiographic progression using modified-vdHS or mTSS?
​
How does real-world evidence differ from randomized controlled trials?
​
How Do You Interpret cDAPSA/DAPSA and MDA?
​
How Do IL-23 and IL-17 Inhibitors Differ In Clinical Efficacy?
MEDICATION REVIEWS
Click a title to watch the review
​
Describe the mechanism of action of guselkumab
​​​
What is Non-Responder Imputation and How is it Utilized in Clinical Trials
​
How is Guselkumab dosed in PsO, PsA, and IBD
​
What is the safety profile of guselkumab in PsO and PsA?
​
What is the efficacy of guselkumab across the GRAPPA domains?
​
JOURNAL CLUBS
Click a title to read the journal
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
​
​
​
Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)
PODCASTS
Click a title to play the podcast
The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD
​
CD64+ Binding: Description, Relevance, and Potential Clinical Implications
​
The Clinical Utility of Guselkumab in Axial PsA
​
The Relative Persistency and Effectiveness of Guselkumab in the Real-World
